As of September 30, 2024, the company had cash and cash equivalents of $34.3 million, including 19.4 million raised through investor exercises of Tranche B warrants and the purchase of new warrants in July 2024, compared to $9.6 million as of December 31, 2023. The company believes its cash balance as of September 30, 2024, is adequate to fund its basic budgeted operations into the second quarter of 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Options Volatility and Implied Earnings Moves Today, November 18, 2024
- Cellectar Biosciences signs strategic supply agreement with NorthStar
- Cellectar, SpectronRx sign agreement to manufacture iopofosine I 131
- CLRB Upcoming Earnings Report: What to Expect?
- Cellectar Biosciences regains compliance with Nasdaq